Arca
Skip to content
Tools
Tools

Leiomyosarcoma

Drug research and approvals for leiomyosarcoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 36 studies of leiomyosarcoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 1 approved and 0 open orphan designations naming it.

  • Recruiting worldwide: 36
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 36 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

Phase 3 4

Phase 2 12 of 21

Phase 1 or earlier 3

How its trials ended

145 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 42 whose ending is known, 29% met their primary endpoint, 12% missed it and 60% stopped early.

  • Ongoing5236%
  • Completed, result not reported4128%
  • Stopped: other or unclear1510%
  • Met its primary endpoint128%
  • Status unknown107%
  • Missed its primary endpoint53%
  • Stopped: enrollment or feasibility53%
  • Stopped: sponsor or business decision53%

Trials authorized in Canada

Newest first; search them all in Canada trials
Sep 26, 2023Docetaxel in previously treated subjects with leiomyosarcoma (ARGSARC): a randomized, double-blind, multi-center phase 3 trialAdi-peg 20 (pegargiminase) / Gemcitabine / DocetaxelPolaris Pharmaceuticals, Inc. (A Subsidiary of Polaris Group)Ongoing
May 26, 2022A phase 2/3 study to evaluate the efficacy and safety of unesbulin in unresectable or metastatic, relapsed or refractory leiomyosarcomaUnesbulin (PTC596)/ DacarbazinePTC TherapeuticsClosed

FDA orphan designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Oct 23, 2015YondelisFor the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing…Janssen Research & Development, LLCApproved

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.